Follow
The researchers found donanemab slowed the decline of cognition and daily function in Alzheimer's patients by 32% after 76 weeks, compared to those who received a placebo.
Taken over 18 months, that 32% slowing of decline could be noticeably impactful for Alzheimer's patients, noted Maria Carrillo, chief science officer at the Alzheimer's Association, who was not involved in the study.
https://www.cnn.com/2021/03/13/health/alzheimers-donanemab-cognitive-decline/index.html
@EileenKCarpenter I don't know, but I am in favor of any good news.
My mother died of Alzheimer's. If something could have slowed it down...!
@estherschindler
I would like to know how it compares to a placebo group on standard therapy, or with both groups getting standard therapy (drugs that boost memory but don’t alter progression).